CHAOJU EYE CARE Reports Annual Results with Net Profit Attributable to Owners of RMB 1.83 Billion, Down 5.96% Year-on-Year

Stock News

03/31

CHAOJU EYE CARE (02219) announced its annual results for the period ending December 31, 2025. The Group recorded revenue of RMB 13.6 billion, a decrease of 3.21% compared to the previous year. Profit attributable to owners of the parent company was RMB 1.83 billion, representing a decline of 5.96% year-on-year. Earnings per share were RMB 0.26. The Board has proposed a final dividend of HK$0.2423 per share.

The Group's revenue from consumer ophthalmic services decreased by 2.4% to RMB 6.9 billion for the year ending December 31, 2025, down from RMB 7.06 billion for the year ending December 31, 2024. This was primarily attributed to pricing adjustments implemented in response to intensified market competition, particularly in refractive surgery services.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1146765491"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1146765491\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1146765491?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 17:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146765491","market":"nz","top_or_hot":-1,"title":"CHAOJU EYE CARE Reports Annual Results with Net Profit Attributable to Owners of RMB 1.83 Billion, Down 5.96% Year-on-Year","media":"Stock News","content":"<p>CHAOJU EYE CARE (02219) announced its annual results for the period ending December 31, 2025. The Group recorded revenue of RMB 13.6 billion, a decrease of 3.21% compared to the previous year. Profit attributable to owners of the parent company was RMB 1.83 billion, representing a decline of 5.96% year-on-year. Earnings per share were RMB 0.26. The Board has proposed a final dividend of HK$0.2423 per share.</p>\n<p>The Group's revenue from consumer ophthalmic services decreased by 2.4% to RMB 6.9 billion for the year ending December 31, 2025, down from RMB 7.06 billion for the year ending December 31, 2024. This was primarily attributed to pricing adjustments implemented in response to intensified market competition, particularly in refractive surgery services.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHAOJU EYE CARE Reports Annual Results with Net Profit Attributable to Owners of RMB 1.83 Billion, Down 5.96% Year-on-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHAOJU EYE CARE Reports Annual Results with Net Profit Attributable to Owners of RMB 1.83 Billion, Down 5.96% Year-on-Year\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-03-31 17:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CHAOJU EYE CARE (02219) announced its annual results for the period ending December 31, 2025. The Group recorded revenue of RMB 13.6 billion, a decrease of 3.21% compared to the previous year. Profit attributable to owners of the parent company was RMB 1.83 billion, representing a decline of 5.96% year-on-year. Earnings per share were RMB 0.26. The Board has proposed a final dividend of HK$0.2423 per share.</p>\n<p>The Group's revenue from consumer ophthalmic services decreased by 2.4% to RMB 6.9 billion for the year ending December 31, 2025, down from RMB 7.06 billion for the year ending December 31, 2024. This was primarily attributed to pricing adjustments implemented in response to intensified market competition, particularly in refractive surgery services.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1209","symbol_name":"保健護理機構","start_time":0,"source_url":"","article_id":"1146765491","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146765491","pubTimestamp":1774949785,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CHAOJU EYE CARE (02219) announced its annual results for the period ending December 31, 2025. The Group recorded revenue of RMB 13.6 billion, a decrease of 3.21% compared to the previous year. Profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1209":"保健护理机构","BK1587":"次新股","02219":"朝聚眼科"},"translate_title":"朝聚眼科公布全年业绩归属于所有者净利润18.3亿元同比下降5.96%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02219":1},"content_text":"CHAOJU EYE CARE (02219) announced its annual results for the period ending December 31, 2025. The Group recorded revenue of RMB 13.6 billion, a decrease of 3.21% compared to the previous year. Profit attributable to owners of the parent company was RMB 1.83 billion, representing a decline of 5.96% year-on-year. Earnings per share were RMB 0.26. The Board has proposed a final dividend of HK$0.2423 per share.\nThe Group's revenue from consumer ophthalmic services decreased by 2.4% to RMB 6.9 billion for the year ending December 31, 2025, down from RMB 7.06 billion for the year ending December 31, 2024. This was primarily attributed to pricing adjustments implemented in response to intensified market competition, particularly in refractive surgery services.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}